Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT04880863 |
| Title | Naptumomab Estafenatox (NAP) in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC (NT-NAP-102-1) |
| Acronym | NT-NAP-102-1 |
| Recruitment | Completed |
| Gender | |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | NeoTX Therapeutics Ltd. |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |